At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating cisplatin, everolimus, and 2 other interventions for Breast Cancer. Completed, enrolled 55 participants across 4 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving cisplatin and paclitaxel together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cisplatin and paclitaxel together with everolimus and to see how well it works in treating patients with metastatic breast cancer.
Study Details
Timeline
Interventions
Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
Taken daily by mouth.
Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
Blood collection